Vertex Pharmaceuticals (VRTX) stock in focus as company secures EU backing to expand label for its cystic fibrosis therapy ...
The stock's rise snapped a four-day losing streak.
Inc to “Hold” from “Buy” and lowered its price target to $31 from $35, over the company’s investment strategy and valuation. While Vertex reported solid quarterly, Stifel noted its plan to accelerate ...